Display options
Cite
Zhu P, Hu C, Hui K, et al. The role and significance of VEGFR2. Onco Targets Ther. 2017;10:4315-4319doi: 10.2147/OTT.S142085.
Zhu, P., Hu, C., Hui, K., & Jiang, X. (2017). The role and significance of VEGFR2. OncoTargets and therapy, 104315-4319. https://doi.org/10.2147/OTT.S142085
Zhu, Panrong, et al. "The role and significance of VEGFR2." OncoTargets and therapy vol. 10 (2017): 4315-4319. doi: https://doi.org/10.2147/OTT.S142085
Zhu P, Hu C, Hui K, Jiang X. The role and significance of VEGFR2. Onco Targets Ther. 2017 Sep 01;10:4315-4319. doi: 10.2147/OTT.S142085. eCollection 2017. PMID: 28919780; PMCID: PMC5590762.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2017 Sep 01;10:4315-4319. doi: 10.2147/OTT.S142085. eCollection 2017.

The role and significance of VEGFR2.

OncoTargets and therapy

Panrong Zhu, Chenxi Hu, Kaiyuan Hui, Xiaodong Jiang

Affiliations

  1. Tumor Laboratory, Department of Oncology, The Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, Jiangsu, China.

PMID: 28919780 PMCID: PMC5590762 DOI: 10.2147/OTT.S142085

Abstract

Tumor development is closely related to angiogenesis, and VEGFR2 plays an important role in tumor angiogenesis. It is broadly expressed in the blood vessels, especially in the microvessels of tumor tissues. Furthermore, VEGFR2 is detected on the surface of the cell membrane in various immune cells, such as dendritic cells, macrophages, and regulatory T cells (Tregs). Tregs, which are one of the key negative regulatory factors in tumor immune microenvironments, show high-level expression of VEGFR2 which participates in the regulation of immunosuppressive function. VEGFR2

Keywords: VEGFR2; anti-angiogenesis; antitumor immunity; regulatory T cell; tumor immune escape; tumor microenvironment

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

  1. Cancer Res. 2009 Mar 15;69(6):2514-22 - PubMed
  2. PLoS One. 2011;6(9):e25668 - PubMed
  3. Vet Immunol Immunopathol. 2016 Oct 1;178:1-9 - PubMed
  4. PLoS One. 2009 Nov 03;4(11):e7669 - PubMed
  5. Clin Immunol. 2013 Jan;146(1):26-33 - PubMed
  6. J Control Release. 2017 Jan 10;245:81-94 - PubMed
  7. J Cancer Res Clin Oncol. 2015 Mar;141(3):465-74 - PubMed
  8. Lung Cancer. 2012 Aug;77(2):306-11 - PubMed
  9. Clin Cancer Res. 2008 Oct 15;14 (20):6674-82 - PubMed
  10. Clin Cancer Res. 2017 Jan 15;23 (2):587-599 - PubMed
  11. Eur J Immunol. 2004 Mar;34(3):623-630 - PubMed
  12. Cancer Immunol Immunother. 2013 Apr;62(4):737-46 - PubMed
  13. PLoS Negl Trop Dis. 2015 Aug 20;9(8):e0003995 - PubMed
  14. Expert Opin Ther Targets. 2012 Jan;16(1):5-13 - PubMed
  15. J Thorac Oncol. 2017 Feb;12 (2):194-207 - PubMed
  16. N Engl J Med. 1971 Nov 18;285(21):1182-6 - PubMed
  17. Sci Rep. 2016 Oct 05;6:34239 - PubMed
  18. Cancer Res. 2013 Jan 15;73(2):539-49 - PubMed
  19. Clin Cancer Res. 2007 Aug 15;13(16):4840-8 - PubMed
  20. PLoS One. 2012;7(12):e51681 - PubMed
  21. Int J Cancer. 2014 Jan 15;134(2):319-31 - PubMed
  22. Target Oncol. 2016 Aug;11(4):501-5 - PubMed
  23. Oncoimmunology. 2013 Aug 1;2(8):e25156 - PubMed
  24. Oncol Lett. 2017 May;13(5):3781-3786 - PubMed
  25. Eur J Immunol. 2010 Jan;40(1):197-203 - PubMed
  26. Clin Chim Acta. 2013 Jan 16;415:337-40 - PubMed
  27. Science. 2003 Feb 14;299(5609):1057-61 - PubMed
  28. Br J Cancer. 2012 Nov 20;107(11):1869-75 - PubMed
  29. Asian Pac J Cancer Prev. 2013;14(8):4607-10 - PubMed
  30. J Immunol Res. 2014;2014:286170 - PubMed
  31. Hum Pathol. 2017 Mar;61:78-89 - PubMed
  32. Int J Cancer. 2011 Jul 15;129(2):507-12 - PubMed
  33. Int Immunol. 2016 Aug;28(8):401-9 - PubMed
  34. Clin Cancer Res. 2009 Mar 15;15(6):2148-57 - PubMed
  35. J Immunol. 2002 Sep 1;169(5):2756-61 - PubMed
  36. J Immunol. 2016 Nov 15;197(10 ):3927-3935 - PubMed
  37. Vaccines (Basel). 2016 Aug 06;4(3):null - PubMed
  38. J Immunol. 2004 Apr 1;172(7):4618-23 - PubMed
  39. Nature. 2011 Jul 13;475(7355):226-30 - PubMed
  40. Oncotarget. 2017 Jul 18;8(29):47440-47453 - PubMed
  41. Cancer Immunol Res. 2014 Jul;2(7):632-42 - PubMed
  42. Int J Cancer. 2012 Feb 15;130(4):857-64 - PubMed
  43. Med Oncol. 2013 Jun;30(2):556 - PubMed
  44. Cancer Immunol Immunother. 2016 May;65(5):587-99 - PubMed
  45. Cell Res. 2017 Jan;27(1):109-118 - PubMed
  46. Genes Immun. 2014 Dec;15(8):511-20 - PubMed
  47. Oncotarget. 2017 Jan 17;8(3):5135-5148 - PubMed

Publication Types